Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The answer, before the caveats
A behavioral health feasibility study is a pre-launch diligence report that quantifies demand, payer mix, competitive saturation, licensure pathway, real estate viability, and pro forma economics for a proposed treatment program in a specific catchment area. Operators commission one before signing a lease, filing a Certificate of Need, or closing on acquisition capital, because the study tells you whether the program can clear state licensure, secure in-network contracts, and hit census targets inside a 12 to 18 month ramp.
The market needs the discipline. SAMHSA’s 2024 NSDUH found that 80% of people who needed treatment for a substance use disorder in 2024 did not get treatment, which sounds like green-field opportunity. It is not. The 2023 NSDUH showed that 48.5 million people aged 12 or older had a SUD, yet operators in Palm Beach County and Asheville still close beds because the unmet-need number does not translate to commercially insured admissions inside a 25-mile drive radius. A feasibility study is what bridges the macro number to the seven-figure decision in front of you.
What actually goes in the deliverable
A real feasibility study is not a 40-page brochure. It is a defensible binder a lender, an investment committee, or a state surveyor can pressure-test. At Atlantic Health Strategies, when our team builds one, we expect to see seven components, each tied to a downstream filing or contract.
- Catchment and demand modeling. Drive-time isochrones (typically 30, 60, and 90 minutes for residential; 20 minutes for outpatient), CDC WONDER county overdose mortality, and SAMHSA prevalence by MSA. KFF’s 2024 state analysis showed opioid death rates ranging from 3.3 per 100,000 in Nebraska to 38.6 in West Virginia. That spread alone tells you why a national pro forma template is malpractice.
- Competitive saturation. Existing bed counts by ASAM level of care, drawn from SAMHSA’s N-SUMHSS (the survey that replaced N-SSATS and N-MHSS in 2021), state licensure rosters, and on-the-ground call audits.
- Payer mix and rate modeling. Commercial penetration by carrier (Optum/UBH, Carelon, Aetna, Magellan), Medicaid MCO carve-outs, and modeled net revenue per patient day by HCPCS code (H0010-H0019 for residential SUD, H0035 for PHP, H0015/S9480 for IOP).
- Licensure pathway with a clock. Which agency, which statute, what the survey looks like, and what the realistic effective date is.
- Accreditation runway. Joint Commission or CARF timing relative to license issuance and payer contracting.
- Real estate and zoning. Fair Housing Act and ADA reasonable accommodation analysis for residential SUD siting.
- Pro forma with sensitivity bands. Census ramp, denial rate, DSO, and labor cost stressed against base case.
How licensure and payer reality reshape the model
Two examples make the point. In Florida, DCF licenses SUD treatment facilities under Chapter 397 while AHCA licenses mental health facilities under Chapter 394, and Florida did not require a Certificate of Need for new behavioral health facilities as of the most recent rule cycle. Compare that to New Jersey and North Carolina, where DHSR and DOH review processes can stretch your effective date well past your lease commencement. Same building, same clinical model, completely different go/no-go math.
Payers move the model just as hard. KFF’s FY 2025 and 2026 Medicaid budget survey reported total Medicaid spending growth of 8.6% in FY 2025 with continued upward pressure from behavioral health care costs, and over half of states raising fee-for-service rates for outpatient behavioral health clinicians. That sounds bullish. But IMD exclusion rules, state-specific rate floors, and MCO contracting cycles mean an operator in Kentucky and an operator in South Carolina face entirely different reimbursement realities for the same ASAM level. A feasibility study that does not name the MCO, the rate, and the credentialing timeline is not a feasibility study. It is a sales document.
As Robin Rudowitz and colleagues at KFF put it bluntly: “Even when states add benefits, access may still be limited by provider shortages and narrow networks.” The narrow network is your problem to solve in diligence, not after Day 90.
What disqualifies a market, and what a study should tell you to walk away from
A feasibility study earns its fee when it tells you no. Real disqualifiers our team has flagged for clients in the last 18 months:
- Saturation at the level of care you want to build. If a 30-minute drive radius already has more than 1.5 licensed residential beds per 1,000 SUD prevalence and three of the incumbents are in-network with the dominant commercial payer, your ramp will not pencil.
- A payer environment that will not credential a new TIN inside 9 months. CAQH credentialing benchmarks plus MCO contracting cycles tell you this before you sign anything.
- A site that cannot clear local zoning or fire marshal review. In Florida, proof of compliance with local zoning ordinances is mandatory prior to even receiving a provisional license. We have seen operators in Texas and Tennessee lose six figures in renovation spend because nobody pulled the zoning letter first.
- An overdose mortality trend moving the wrong direction relative to your acuity model. National overdose deaths fell roughly 27% from 2023 to 2024 per CDC’s NCHS, with an estimated 80,391 drug overdose deaths in 2024. That is good news for public health. It also means a residential detox pro forma built on 2022 admission patterns is already stale.
- A founder team without a credentialed Medical Director or a defensible clinical leadership bench. No surveyor cares about your deck.
A study that does not have the spine to recommend a no-go is not worth the engagement letter.
Frequently asked questions
How much does a behavioral health feasibility study cost and how long does it take?
For a single-site, single-level-of-care program, expect roughly $25,000 to $75,000 and 4 to 8 weeks. Multi-site, multi-state, or CON-state engagements run higher and longer because the licensure analysis alone is bespoke per jurisdiction. Anyone quoting you a flat $7,500 fee is selling a market brief, not a feasibility study.
What’s the difference between a feasibility study, a market study, and a CON application?
A market study quantifies demand and competition. A feasibility study does that plus licensure, payer modeling, pro forma, and real estate viability, and it ends in a go / no-go / conditional recommendation. A Certificate of Need application is a regulatory filing in CON states that draws on the feasibility study but is submitted to the state agency for approval to add capacity.
When in the development lifecycle should I commission a feasibility study, before or after site selection?
Before. The site decision should be an output of the study, not an input. We have seen operators in Kentucky and South Carolina sign leases first and then discover the zoning overlay or the dominant MCO’s closed panel makes the location unworkable. Order matters.
Can a feasibility study satisfy lender or PE diligence requirements?
Yes, if it is built for that audience. Lenders and PE diligence teams want defensible inputs, named sources, sensitivity bands, and an author who will sit on a call and defend the assumptions. A study built only for internal use rarely survives a credit committee. Build it once, build it right.
What disqualifies a market, and will a feasibility study tell me to walk away?
A good one will. Saturation at your target ASAM level, a closed commercial payer panel, a non-permissive zoning environment, a state licensure timeline that breaks your construction draw schedule, or an overdose mortality and prevalence trend that contradicts your acuity assumptions are all walk-away triggers. The study exists to protect your capital, not to validate a decision you already made.
References
- SAMHSA, Release of the 2024 National Survey on Drug Use and Health (NSDUH)
- NACo summary, SAMHSA 2023 NSDUH key findings
- KFF, Opioid Overdose Deaths: National Trends and Variation by Demographics and States
- KFF, Medicaid Enrollment & Spending Growth: FY 2025 & 2026
- KFF, Medicaid Mental Health and Substance Use: Expansion Trends and the Fiscal Pressure Ahead
- CDC NCHS, U.S. Overdose Deaths Decrease Almost 27% in 2024
- CDC NCHS, Provisional County Drug Overdose Deaths
- SAMHSA, National Substance Use and Mental Health Services Survey (N-SUMHSS)
- Florida Behavioral Health Licensure Overview (Chapter 397 / Chapter 394, DCF and AHCA)